Summary of Study ST000790

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000574. The data can be accessed directly via it's Project DOI: 10.21228/M8GD58 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000790
Study TitleIdentifying metabolic adaptations characteristic of multiple myeloma cells via targeted sphingolipids concentrations from bone marrow and peripheral plasma
Study SummaryWill be assessing the targeted sphingolipids concentrations of high risk versus low risk smoldering myeloma patients based on peripheral blood plasma and bone marrow plasma.
Institute
Mayo Clinic
Last NameGonsalves
First NameWilson
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailgonsalves.wilson@mayo.edu
Phone507-266-0792
Submit Date2017-07-11
Analysis Type DetailLC-MS
Release Date2019-07-17
Release Version1
Wilson Gonsalves Wilson Gonsalves
https://dx.doi.org/10.21228/M8GD58
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000574
Project DOI:doi: 10.21228/M8GD58
Project Title:Mayo Pilot and Feasibility: Identifying metabolic adaptations characteristic of multiple myeloma cells via mass spectrometry-based metabolite profiling
Project Summary:Multiple myeloma (MM) is a clonal plasma cell malignancy that remains incurable in most afflicted patients. It can be preceded by an asymptomatic, premalignant stage known as smoldering multiple myeloma (SMM) that does not require therapy but has an increased life-long risk of progression to MM. However, one-third of SMM patients are “high risk” for imminent progression to MM within two years of diagnosis compared to the remainder of SMM patients who continue on an indolent asymptomatic course for several years. The diagnosis of MM cannot be made until they experience overt end-organ damage such as renal failure, lytic bone destruction, anemia and hypercalcemia. Currently, we lack sensitive biomarkers that can identify all SMM patients at high risk of progression to MM. Being able to identify high risk SMM patients could allow us to initiate systemic chemotherapy before they progress to MM. Cancer cells undergo distinct metabolic adaptations to meet the augmented cellular demand for energy and nutrients created by their increased rates of cellular proliferation. The presence of an altered cellular metabolism in clonal PCs from MM patients and its role as an essential factor in the progression of SMM to MM is unknown. We hypothesize that the clonal PCs in high risk SMM patients likely have an altered metabolic phenotype similar to those present in MM patients but different when compared to clonal PCs in the remainder of the SMM patients whose clinical course remains indolent. Thus, two specific aims are proposed in this study: Aim 1 will verify if there are differences in the regulation of the metabolic pathways in clonal PCs from MM patients compared to normal PCs from healthy patients; Aim 2 will assess whether the clonal PCs from high risk SMM patients bear a distinct metabolic phenotype compared to clonal PCs from standard risk SMM patients.
Institute:Mayo Clinic
Last Name:Gonsalves
First Name:Wilson
Address:200 First St. SW, Rochester, Minnesota, 55905, USA
Email:gonsalves.wilson@mayo.edu
Phone:507-266-0792

Subject:

Subject ID:SU000815
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id grouping
SA043517ms6273-32Quick Progressors
SA043518ms6273-33Quick Progressors
SA043519ms6273-35Quick Progressors
SA043520ms6273-30Quick Progressors
SA043521ms6273-29Quick Progressors
SA043522ms6273-22Quick Progressors
SA043523ms6273-24Quick Progressors
SA043524ms6273-38Quick Progressors
SA043525ms6273-42Quick Progressors
SA043526ms6273-48Quick Progressors
SA043527ms6273-49Quick Progressors
SA043528ms6273-50Quick Progressors
SA043529ms6273-47Quick Progressors
SA043530ms6273-45Quick Progressors
SA043531ms6273-20Quick Progressors
SA043532ms6273-43Quick Progressors
SA043533ms6273-41Quick Progressors
SA043534ms6273-26Quick Progressors
SA043535ms6273-11Quick Progressors
SA043536ms6273-19Quick Progressors
SA043537ms6273-13Quick Progressors
SA043538ms6273-9Quick Progressors
SA043539ms6273-7Quick Progressors
SA043540ms6273-2Quick Progressors
SA043541ms6273-3Quick Progressors
SA043542ms6273-5Quick Progressors
SA043543ms6273-15Quick Progressors
SA043544ms6273-12Quick Progressors
SA043545ms6273-17Quick Progressors
SA043546ms6273-16Quick Progressors
SA043547ms6273-44Slow Progressors
SA043548ms6273-8Slow Progressors
SA043549ms6273-46Slow Progressors
SA043550ms6273-6Slow Progressors
SA043551ms6273-21Slow Progressors
SA043552ms6273-18Slow Progressors
SA043553ms6273-4Slow Progressors
SA043554ms6273-23Slow Progressors
SA043555ms6273-25Slow Progressors
SA043556ms6273-40Slow Progressors
SA043557ms6273-34Slow Progressors
SA043558ms6273-28Slow Progressors
SA043559ms6273-14Slow Progressors
SA043560ms6273-31Slow Progressors
SA043561ms6273-27Slow Progressors
SA043562ms6273-36Slow Progressors
SA043563ms6273-39Slow Progressors
SA043564ms6273-1Slow Progressors
SA043565ms6273-37Slow Progressors
SA043566ms6273-10Slow Progressors
Showing results 1 to 50 of 50

Collection:

Collection ID:CO000809
Collection Summary:In order to analyze the metabolites of clonal PCs (intracellular) and BM plasma (extracellular) separately, they have to be separated out from the BM samples. Thus, upon acquiring the BM samples from patients they will be placed in centrifuged at 2500 rpm for 10 minutes to separate out the plasma from the cellular fraction. The separated BM plasma is then stored in separate vials and snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for further analysis. The leftover cellular component present as a pellet will be washed and reconstituted with an equal volume of RPMI 1640 medium. Erythrocytes are lysed using ammonium chloride lysing solution. After incubation on ice for 5 min, the cell suspension is diluted with RPMI medium. The cells are again pelleted by centrifugation and then suspended in RoboSep buffer (250ml PBS, 2% BSA, 1mM EDTA). The clonal CD138 positive PCs are purified using positive selection by mixing the cells with a CD138 positive selection cocktail and anti-CD138 magnetic-activated cell separation microbeads (ROBOSEP™ cell separation system, StemCell Technologies Inc) in the automated RoboSep cell separation system. The purified samples containing only CD138 positive cells are re‐suspended and then centrifuged to form a cell pellet. The goal will be to obtain at least 1-2 x 107 clonal PCs per sample. The cell pellet will be snap frozen under liquid nitrogen for 20 seconds before storing at -80οC for further analysis. Both the BM plasma samples as well as the clonal PCs pellet will be provided to the metabolomics core for sample preparation for LC-MS analysis. For Aim 2, we will be using stored BM samples from SMM patients that have already had their BM plasma and clonal PCs separated from each other and stored at -80οC. It is important to note that all these samples were collected and frozen in a timely manner. Furthermore consistency in sample collection, storage and processing is imperative for the optimal conduct of metabolomics-based experiments. This ensures that all samples being analyzed and compared with each other would have been manipulated similarly, limiting any handling biases. All patient samples in the Predolin Foundation Biobank were collected and stored by following a standardized operating procedure. BM samples were processed for BM plasma separation and clonal PCs enrichment but were then immediately snap frozen for storage at -80οC within approximately 3 hours of collection from the patient. All samples were collected in patients who have been fasting for at least 6 to 8 hours prior. To further ensure consistency in our analysis of this study, we will only use samples that have never been thawed since initial storage to preserve the stability of the metabolites originally present in the samples.
Sample Type:Bone marrow

Treatment:

Treatment ID:TR000829
Treatment Summary:We will use matched BM plasma and purified clonal marrow PCs from the BM samples of SMM patients collected at the time of their diagnosis and stored within the Mayo Clinic Predolin Foundation Biobank. We will select BM samples from patients with SMM who progressed to MM within 2 years of their samples being collected and stored; this will constitute the high risk SMM group. We will also select BM samples from SMM patients who have not progressed to MM within at least 2 years of follow up of their samples being collected and stored; this will constitute the standard risk SMM group. The strength of this approach is that we will utilize stored SMM samples from one of the most comprehensively characterized monoclonal gammopathy biobanks available. Secondly, all samples will be obtained from collection dates at least 2 years prior in order to ensure adequate follow-up time to assess their current clinical status. This would avoid the need to prospectively collect samples from SMM patients and clinically follow them for a number of years before we are able to gauge who were clinically high or standard risk for progression. There are over 700 SMM patients who have had their BM samples collected and stored in the biobank from 1996 to 2013; more than half these patients have progressed to MM.

Sample Preparation:

Sampleprep ID:SP000822
Sampleprep Summary:sphingolipids concetrations

Combined analysis:

Analysis ID AN001258
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity BEH C8 (150 x 2mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Thermo Quantum Ultra
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH000876
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C8 (150 x 2mm,1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS001151
Analysis ID:AN001258
Instrument Name:Thermo Quantum Ultra
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo